2019
DOI: 10.1136/bmjophth-2019-000398
|View full text |Cite
|
Sign up to set email alerts
|

Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review

Abstract: Age-related macular degeneration is the leading cause of vision loss in the developed world, with the expected number of affected elderly individuals reaching 17.8 million. Antivascular endothelial growth factor (anti-VEGF) injection therapy has been instrumental in treating a disease process that was previously thought to be untreatable. Over the past two decades, landmark studies have demonstrated the efficacy of different anti-VEGF medications and investigated the optimal dosing regimen and delivery mechani… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
90
0
7

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 94 publications
(99 citation statements)
references
References 38 publications
1
90
0
7
Order By: Relevance
“…When dry AMD advances, the RPE degenerates almost completely and geographic atrophy characterized by RPE hypopigmentation and absence of the RPE sets in [9]. The wet types of AMD are characterized by choroidal neovascularization which causes bleedings, fluid accumulation and fibrosis within the macula [10]. Taken together, these RPE changes suggest that RPE dysfunction has a central role in AMD pathology and progression.…”
Section: Introductionmentioning
confidence: 99%
“…When dry AMD advances, the RPE degenerates almost completely and geographic atrophy characterized by RPE hypopigmentation and absence of the RPE sets in [9]. The wet types of AMD are characterized by choroidal neovascularization which causes bleedings, fluid accumulation and fibrosis within the macula [10]. Taken together, these RPE changes suggest that RPE dysfunction has a central role in AMD pathology and progression.…”
Section: Introductionmentioning
confidence: 99%
“…Because of the critical consequences about the visual loss caused by AMD, especially advanced AMD (atrophic/dry or neovascular/wet), it is necessary to study its etiology and mechanism, then to development early diagnostic methods and effective treatments. Nowadays, vascular endothelial growth factor (VEGF) inhibitors are widely recognized as effective drugs in clinical application for CNV (wet AMD) [41][42][43]. It is well known that VEGF is involved in wet AMD development because that the formation of angiogenesis and vascular permeability can lead to fluid leakage across the blood vessels, and visual loss in the final [44].…”
Section: Discussionmentioning
confidence: 99%
“…Due to the severe consequences of vision loss caused by AMD, especially advanced AMD (atrophic/dry or neovascular/wet), it is necessary to study its etiology and mechanism, and then develop early diagnostic methods and effective treatments. Today, VEGF inhibitors have been widely regarded as effective drugs in clinical application for CNV (wet AMD) [3,73,74]. Therefore, identifying some novel detection markers and target drugs for some different types of AMD is the focus of current and future research.…”
Section: Discussionmentioning
confidence: 99%